Drugs / Xcellerate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00039299 | Mar 2002 → Jun 2003 | prostate cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xcellerate | “Determine the safety of activated autologous T cells (Xcellerate) therapy in patients with hormone-refractory prostate cancer.” NCT00039299 ↗ |
| Modality | Cell therapy | “activated autologous T cells (Xcellerate) therapy” NCT00039299 ↗ |